| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| Estimated average burden |           |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*   Woock John |         |          | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Axonics Modulation Technologies, Inc.</u> [<br>AXNX ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner<br>X Officer (give title Other (specify<br>below) below) |  |  |  |  |
|---|---------|----------|--|---|--|--|--|--|
| (Last) (First) (Middle)<br>26 TECHNOLOGY DRIVE        |         | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year)<br>11/27/2020   | Chief Marketing Officer   |  |  |  |  |
| (Street)  |         |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Individual or Joint/Group Filing (Check Applicable Line)   |  |  |  |  |
| IRVINE  | CA      | 92618    |  | X Form filed by One Reporting Person  |  |  |  |  |
| (City)  | (State) | (Zip)    |  | Form filed by More than One Reporting<br>Person   |  |  |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   |        |               |                          | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|------------------------------|---|--------|---------------|--------------------------|---|---|---|
|                                 |  |   | Code                         | v | Amount | (A) or<br>(D) | Price                    | Transaction(s)<br>(Instr. 3 and 4)  |   | (insti. 4)  |
| Common Stock                    | 11/27/2020                                 |   | М                            |   | 10,000 | A             | \$1.42                   | 77,348  | D   |   |
| Common Stock                    | 11/27/2020                                 |   | <b>S</b> <sup>(1)</sup>      |   | 2,400  | D             | \$43.7946 <sup>(2)</sup> | 74,948  | D   |   |
| Common Stock                    | 11/27/2020                                 |   | <b>S</b> <sup>(1)</sup>      |   | 100    | D             | \$45.49                  | 74,848  | D   |   |
| Common Stock                    | 11/27/2020                                 |   | <b>S</b> <sup>(1)</sup>      |   | 7,500  | D             | \$44.9414 <sup>(3)</sup> | 67,348  | D   |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |        | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D)    | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$1.42  | 11/27/2020                                 |   | М                            |   |     | 10,000 | (4)  | 08/25/2027         | Common<br>Stock   | 10,000                                 | \$0.00  | 4,178  | D  |  |

Explanation of Responses:

1. This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 22, 2020.

2. This transaction was executed in multiple trades at prices ranging from \$43.36 to \$44.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from \$44.47 to \$45.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The shares subject to the option vest over a period of four years. 7,800 of the shares subject to the option vested on July 21, 2017 and the remainder vest at a rate of 1/36th per month commencing on July 21, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

## Remarks:

/s/ Dan Dearen, as Attorney-in-Fact for John Woock, Ph.D <u>12/01/2020</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.